The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement

Wang, Yuqiao; Zhou, Ying; Hu, Zhiyuan

doi:10.1515/jtim-2017-0029

Cited by 24 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since Cristofanilli et al [ 22 ] demonstrated the prognostic meaning of CTCs in metastatic breast cancer using the CellSearch device (Menarini Silicon Biosystems, Castel Maggiore, Italy) for CTC enumeration, such prognostic value has been demonstrated for several solid cancer entities like prostate, ovarian, and colorectal cancer [ 23 ]. In addition to enumeration, it is meanwhile well-known that further molecular characterization of CTCs provides valuable information about the CTC metabolism in the context of therapy resistance mechanisms [ 24 ••, 25 •] and phenotype changes like EMT and tumor stem cell formation [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma

et al. 2018

View full text Add to dashboard Cite

Purpose of ReviewLiquid biopsy analyses based on circulating cell-free nucleic acids, circulating tumor cells or other diseased cells from organs, and exosomes or other microvesicles in blood offer new means for non-invasive diagnostic applications. The main goal of this review is to explain the importance of preserving whole blood specimens after blood draw for use as liquid biopsies, and to summarize preservation solutions that are currently available.Recent FindingsDespite the great potential of liquid biopsies for diagnostics and disease management, besides non-invasive prenatal testing (NIPT), only a few liquid biopsy applications are fully implemented for routine in vitro diagnostic testing. One major barrier is the lack of standardized pre-analytical workflows, including the collection of consistent quality blood specimens and the generation of good-quality plasma samples therefrom. Broader use of liquid biopsies in clinical routine applications therefore requires improved pre-analytical procedures to enable high-quality specimens to obtain unbiased analyte profiles (DNA, RNA, proteins, etc.) as they are in the patient’s body.SummaryA growing number of stabilizing reagents and dedicated blood collection tubes are available for the post-collection preservation of circulating cell-free DNA (ccfDNA) profiles in whole blood. In contrast, solutions for the preservation of circulating tumor cells (CTC) that enable both, enumeration and molecular analyses are rare. Solutions for extracellular vesicle (EV) populations, including exosomes, do not yet exist.

show abstract

Section: Introductionmentioning

confidence: 99%

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There is no accurate and efficient clinical biomarker of GC. Other gastrointestinal biomarkers or early detection methods were also not applied in GC[26-28]. Therefore, the aim of our study was to investigate whether LOX and HIF1α could be used as biomarkers of GC.…”

Section: Discussionmentioning

confidence: 99%

Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer

Han¹,

Chen²,

Qin³

et al. 2019

WJG

View full text Add to dashboard Cite

BACKGROUND Gastric cancer (GC) is one of the main causes of cancer mortality worldwide. Recent studies on tumor microenvironments have shown that tumor metabolism exerts a vital role in cancer progression. AIM To investigate whether lysyl oxidase (LOX) and hypoxia-inducible factor 1α (HIF1α) are prognostic and predictive biomarkers in GC. METHODS A total of 80 tissue and blood samples were collected from 140 patients admitted to our hospital between August 2008 and March 2012. Immunohistochemical staining was performed to measure the expression of LOX and HIF1α in tumor and adjacent tissues collected from patients with GC. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis was used to detect the mRNA expression levels of LOX and HIF1α in patients with GC. In addition, single-factor analysis was applied to analyze the relationship between LOX, HIF1α and prognosis of GC. RESULTS Immunohistochemical staining suggested that the expression levels of LOX and HIF1α increased in tumor tissues from patients with GC. QRT-PCR analysis indicated that mRNA expression of LOX and HIF1α was also upregulated in tumor tissues, which was in accordance with the above results. We also detected expression of these two genes in blood samples. The expression level of LOX and HIF1α was higher in patients with GC than in healthy controls. Additional analysis showed that the expression level of LOX and HIF1α was related to the clinicopathological characteristics of GC. Expression of LOX and HIF1α increased with the number of lymph node metastases, deeper infiltration depth and later tumor–node–metastasis stages. Single-factor analysis showed that high expression of LOX and HIF1α led to poor prognosis of patients with GC. CONCLUSION LOX and HIF1α can be used as prognostic and predictive biomarkers for GC.

show abstract

“…The detection of CTCs in different cancer types including colorectal cancer, lung cancer, and prostate cancer correlates with different pathological stages, clinical outcome, and patient's survival. [141][142][143][144][145][146] The first and only actionable test for detecting CTCs in cancer patients is the CellSearch system, which is applicable as a self-determining forecaster of overall and progression-free survival in metastatic breast, prostate, and colorectal cancer. 147,148 In addition to CTC detection, ctDNA is a gifted approach for primary cancer diagnosis.…”

Section: Clinical Applications Of Liquid Biopsymentioning

confidence: 99%

Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors

et al. 2020

View full text Add to dashboard Cite

Blood test is a kind of liquid biopsy that checks cancer cells or cancer nucleic acids circulating freely from cells in the blood. A liquid biopsy may be used to distinguish cancer at early stages and it could be a game-changer for both cancer diagnosis and prognosis strategies. Liquid biopsy tests consider several tumor components, such as DNA, RNA, proteins, and the tiny vesicles originating from tumor cells. Actually, liquid biopsy signifies the genetic alterations of tumors through nucleic acids or cells in various body fluids, including blood, urine, cerebrospinal fluid, or saliva in a noninvasive manner. In this review, we present an overall description of liquid biopsy in which circulating tumor cells, cell-free nucleic acids, exosomes, and extrachromosomal circular DNA are included.

show abstract

The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement

Cited by 24 publications

References 18 publications

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma

Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer

Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors

Contact Info

Product

Resources

About